cabozantinib renal cell carcinoma - Yahoo Search Results

Ads
related to: cabozantinib renal cell carcinoma
CABOMETYX® (cabozantinib) - Official Physician Website

www.cabometyxhcp.com
Consider CABOMETYX® For Your Patients. Official Website for Healthcare Professionals. Support And Resources For Your Eligible Patients. Learn More Including Safety Information.
Types: HCP Resources, Contact A Rep, Prescribing & Safety Info, Clinical Guidelines
Treatment Guide
Download A Treatment

Management Guide.

Efficacy & Safety Data
Read More About Efficacy & Safety

Data For CABOMETYX®.

Watch CABOMETYX® Videos
Watch A Series Of Videos

For Healthcare Professionals.

Contact A Rep
Contact A Rep To Learn

More About CABOMETYX®

Patient Access
Learn About Access Services For

Your Eligible CABOMETYX® Patients.

Prescribing & Safety Info
Download The Prescribing

Information For CABOMETYX®.
Renal Cell Carcinoma Treatment - Official Patient Website

RCCtreatmentoption.com
Learn About This Treatment Option For Certain Patients With Renal Cell Carcinoma. FDA-Approved First-Line Treatment Option For Certain Patients With Renal Cell Carcinoma.
FDA-Approved · Newly Diagnosed Patients · Patient-Focused Website · Information For Patients
Types: Side Effects, Clinical Trial Results, Patient Site, Dosing Information
How This Treatment Works
FAQs
Clinical Trial Info
Dosing Information
Patient Resources

Search results

- Exelixis' Growth Trajectory Depends on Leading Innovations in Cancer Treatments
  GuruFocus.com via Yahoo Finance· 2 months ago
  Exelixis Inc. (NASDAQ:EXEL) is a pharmaceutical company headquartered in Alameda, California that...
- Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal
  Zacks via Yahoo Finance· 1 year ago
  Shares of Exelixis, Inc. EXEL were down 0.17% on Mar 3 after the company announced the failure of...
- Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More
  Zacks via Yahoo Finance· 1 year ago
  The biotech sector was in focus with key pipeline and regulatory updates. Among these, BMRN was down...
- Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
  Benzinga via Yahoo Finance· 1 year ago
  Exelixis Inc (NASDAQ: EXEL) announced that the phase 3 CONTACT-03 study did not meet its primary...
- Is Exelixis' (EXEL) Growth Story Likely to Continue?
  Zacks via Yahoo Finance· 2 years ago
  Exelixis EXEL, an oncology-focused company, maintains momentum on the back of the solid performance of its lead drug Cabometyx amid stiff competition...
- Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
  Zacks via Yahoo Finance· 9 months ago
  Exelixis, Inc. EXEL and partner Ipsen announced that the late-stage CONTACT-02 study achieved one of...
- Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
  Zacks via Yahoo Finance· 3 months ago
  Exelixis, Inc. EXEL reported earnings of 33 cents per share in the fourth quarter of 2023, which...
- Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer
  Benzinga via Yahoo Finance· 2 years ago
  Exelixis Inc (NASDAQ: EXEL) announced detailed results from the COSMIC-313 Phase 3 trial...
- Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
  Zacks via Yahoo Finance· 1 week ago
  Exelixis, Inc. EXEL reported lower-than-expected results for the first quarter. Its shares fell 7%...
- Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx
  Zacks via Yahoo Finance· 4 months ago
  Exelixis, Inc. EXEL announced that it has successfully defended an EU patent for Cabometyx...